In a new preclinical study, researchers from the Perelman School of Medicine at the University of Pennsylvania found that as a method of reprogramming patients’ autoimmune cells to attack their blood cancer, CAR-T cell therapy may improve the effectiveness of surgical treatment of solid tumors. The relevant research results were published in the journal Science Advances, and the title of the paper was “Chiric antigen receiver T cells as adjuvant-therapy…
car-t
New Co-stimulatory Signal Enables CAR-T to Show Its Potential in the Treatment of Solid Tumors
Chimeric antigen receptor (CAR) expressing T cells (CAR-T therapy) is one of the major breakthroughs in the field of cancer treatment in recent years, and has achieved excellent results in the treatment of blood cancer. CAR is like a “GPS navigation system” for T cells, so that T cells can quickly locate tumor cells that are good at camouflage, so as to find and kill them. So far, two CAR-T…
Nature: “Reconstruct” T cells into the Brain and Attack “Escape” Cancer Cells
For glioblastoma, immunotherapy faces a particular challenge—the blood-brain barrier blocks T cells from entering the brain to prevent brain inflammation that can be life-threatening. This “protective measure” is beneficial under normal conditions, but it prevents T cells from reaching the glioblastoma, leaving immunotherapy useless. On September 5th, Nature published an article entitled “A homing system targets therapeutic T cells to brain cancer”, which reveals a new solution from a…